Breaking

At least one killed and several embassies damaged in ‘barbaric’ Russian missile barrage on Kyiv, Ukraine says
Macron tells cyclone-hit Mayotte islanders to be grateful they are French after facing jeers
At least one dead after car plows into German Christmas market, public broadcaster says
Italy’s deputy prime minister found not guilty of kidnapping in migrant case
A ‘pro-America’ India could help New Delhi win over Trump
Brunswick Exploration Closes Upsized Non-Brokered Private Placement of $4.8M
Skyharbour Announces Closing of Private Placement for Gross Proceeds of C$10 Million
FALCO ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT

World News
Science
Investing
Business
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Brunswick Exploration Closes Upsized Non-Brokered Private Placement of $4.8M

December 21, 2024

FALCO ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT

December 21, 2024

Skyharbour Announces Closing of Private Placement for Gross Proceeds of C$10 Million

December 21, 2024

Fill Out & Get More Relevant News

Your name

Your email

Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.
Categories
- Business (766)
- Investing (1,535)
- Science (573)
- World News (1,838)

Disclaimer: digitaltradecenter.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest Posts
- Privacy Policy
- Terms & Conditions

Copyright © 2024 digitaltradecenter.com | All Rights Reserved

Top

World News
Science
Investing
Business

Type above and press Enter to search. Press Esc to cancel.